REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
03/21/2026
Back to search
Official data from USPTO
CTI BIOPHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
CTI BIOPHARMA
ST13
US500000086282220Class
5, 41, 42
Filing
86282220
Registration
5166752
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
62
Latest update
03/22/2026
Classification
Registered
Trademark type
Word
Nice classes
5, 41, 42
Filing date
05/15/2014
Registration date
03/21/2017
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/24/2023
Last transaction
03/22/2026
Responsible office
United States Patent and Trademark Office
Status code
702
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
12/18/2015
First use in commerce
12/18/2015
Drawing code
4
Owner type
03
Owner location
SEATTLE, WA, US
Examiner
LEE, YATSYE ISADORA
Law office
L70
Current location
TMEG LAW OFFICE 107
Holders and representatives
Holders
CTI BIOPHARMA CORP.
Cell Therapeutics, Inc.
Representatives
Frances M. Jagla CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
Technical classification
Nice Classes
Class 5Class 41Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations and substances for the treatment of cancer and for use in chemotherapy treatment; Pharmaceutical preparations and substances for the treatment of immunologicaloncologicalinflammatory and infectious diseases and disorders; Pharmaceutical preparations used for the treatment of conditions secondary to the oncologicimmunological and inflammatory diseases; Pharmaceutical preparations and substances for the management and treatment of pain accompanying either the disease process or the associated treatment regimens
Class 41
Conducting seminarsclassesworkshopstraining in the fields of pharmaceutical products and the treatment of medical disordersthe life sciencesclinical trialshealthmedicineoncologyhematologycancergenetic disordersproviding course materials in connection therewith; Online publications in the nature of articlesjournalsnewsletters in the fields of pharmaceuticals and the treatment of medical disordersthe life sciencesclinical trialshealthmedicineoncologyhematologycancergenetic disorders
Class 42
Researchdevelopmentengineeringtestingproduct evaluationinspection in the field of pharmaceutical preparations and products; Pharmaceutical research and development; Providing technical consultation in the field of pharmaceutical product research and development; Medical and scientific researchconducting clinical trials for others for pharmaceutical preparations used for the treatment of cancerimmunologicalinflammatory and infectious diseasespain; Scientific researchconsultingadvice in the fields of biotechnologypharmaceutical research and developmentthe life sciences; Pharmaceuticalmedical and laboratory research services in the fields of pharmaceuticalscancergenetic disordersthe life sciences; Providing medical testing services for research purposes and medical and scientific research information in the fields of pharmaceuticalsthe life sciencesclinical trialsmedicineoncologyhematologycancerdisease classificationgenetic disorders; and consultation related to the foregoing
Publications
History of USPTO decisions and trademark events.
62 publications found
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
03/24/2023
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
03/24/2023
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
03/24/2023
E815
TEAS SECTION 8 & 15 RECEIVED
09/13/2022
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
03/21/2022
CORV
REVIEW OF CORRESPONDENCE COMPLETE - ADDRESS UPDATED
06/12/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
05/14/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/14/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
05/14/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
05/14/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
05/14/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
05/06/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/06/2020
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
05/06/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
05/06/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
05/06/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
05/06/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
03/21/2017
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
02/16/2017
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
02/15/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/25/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/25/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/19/2017
EEXT
SOU TEAS EXTENSION RECEIVED
01/19/2017
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/26/2016
GNRT
NON-FINAL ACTION E-MAILED
09/26/2016
CNRT
SU - NON-FINAL ACTION - WRITTEN
09/26/2016
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
09/02/2016
SUPC
STATEMENT OF USE PROCESSING COMPLETE
09/01/2016
EX1G
SOU EXTENSION 1 GRANTED
09/01/2016
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
08/31/2016
IUAF
USE AMENDMENT FILED
08/08/2016
EXT1
SOU EXTENSION 1 FILED
08/08/2016
EEXT
SOU TEAS EXTENSION RECEIVED
08/08/2016
EISU
TEAS STATEMENT OF USE RECEIVED
08/08/2016
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
05/06/2016
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
05/06/2016
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
02/09/2016
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/15/2015
PUBO
PUBLISHED FOR OPPOSITION
12/15/2015
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/25/2015
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
11/06/2015
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/26/2015
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/20/2015
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/19/2015
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
10/19/2015
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
04/29/2015
GNFR
FINAL REFUSAL E-MAILED
04/29/2015
CNFR
FINAL REFUSAL WRITTEN
04/29/2015
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/11/2015
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/11/2015
ALIE
ASSIGNED TO LIE
03/06/2015
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/26/2015
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/31/2014
GNRT
NON-FINAL ACTION E-MAILED
08/31/2014
CNRT
NON-FINAL ACTION WRITTEN
08/31/2014
DOCK
ASSIGNED TO EXAMINER
08/31/2014
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
07/02/2014
MPMK
NOTICE OF PSEUDO MARK E-MAILED
05/29/2014
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/28/2014
NWAP
NEW APPLICATION ENTERED
05/19/2014
Continuous trademark protection
Get notified about every new filing that threatens CTI BIOPHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.